APR 02, 2018 6:37 PM PDT

Treating Rare Pediatric Cancers

WRITTEN BY: Nouran Amin

Research published in The Lancet Oncology explains how the drug Larotrectinib can treat cancer cells that have a specific fusion of two genes. Larotrectinib received FDA designation and can treat any cancer type with a fusion gene. "In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it's not supposed to be and that causes the cells to grow uncontrollably. What's unique about the drug is it is very selective; it only blocks TRK receptors," said lead investigator Dr. Ted Laetsch, a Professor of Pediatrics at Harold C. Simmons Comprehensive Cancer Center.

Larotrectinib is part of a group molecules designated as ‘kinase inhibitors’ which work to cut back on the enzyme actions of cellular mechanisms. In this case, Larotrectinib targets TRK fusions which are present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors. Some TRK fusions occur in only a small percentage of common adult cancers however the rest are more commonly seen in rare pediatric cancers including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer. "Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink. The nearly universal response rate seen with larotrectinib is unprecedented," explains Dr. Laetsch.

One child treated with Larotrectinib was 13-year-old aspiring fashion designer Briana Ayala of El Paso. Briana had a rare tumor located in her abdomen and wrapped around her aorta, which made it risky for surgical operation. So, Briana and her family were there encouraged to visit Children’s Health in Dallas, TX where she underwent a specialized operation that removed only portions of her aorta and most of the tumor. Unfortunately, this did not treat Briana’s cancer as it began to return. With no treatments available, Dr. Laetsch sent Briana’s tumor for genetic testing where it was analyzed to have a TRK fusion making it possible to be treated by Larotrectinib

After Briana’s enrollment in phase 1 clinical trial of the new drug, results have shown that swelling in her abdomen has been diminished along with a shrunken tumor. "These are the kind of amazing responses we've seen with larotrectinib," said Dr. Laetsch, "and this is why I'm so excited about it."

What’s particularly unique about larotrectinib is it doesn’t lead to severe side effects like most other cancer therapeutics and for many patients the response was long-lasting. "For some of the targeted drugs in the past, many patients responded initially, but then resistance developed quickly. To date, the response to this drug seems to be durable in most patients," said Dr. Laetsch.

Sources: The Lancet Oncology, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Teenage Cannabis Use May Prime the Brain to Enjoy Cocaine
New research has found that teenage cannabis use may make the brain more susceptible to the effects of cocaine. "It ...
MAY 09, 2020
Cancer
MAY 09, 2020
Examining a Combination Therapy Against Gastric Cancer
Often when it comes to treatments for cancer, designing or discovering new leads can take years. One of the common pract ...
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Fecal Transplant Helps Fight off Antibiotic Resistance
Fecal transplants work by transporting fecal matter from healthy donors to those who are less healthy. Now, a study has ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Drug Targets Off Episodes of Parkinson
A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred ...
Loading Comments...